Atomoxetine in Early Pregnancy and the Prevalence of Major Congenital Malformations: A Multinational Study

Gabriella Bröms, MD, PhD; Sonia Hernández-Díaz, MD, DrPH; Krista F. Huybrechts, MS, PhD; Brian T. Bateman, MD, MSc; Eskild Bendix Kristiansen, MSc; Kristjana Einarsdóttir, PhD; Anders Engeland, MSc, PhD; Kari Furu, MScPharm, MPH, PhD; Mika Gissler, MSocSc, PhD; Pär Karlsson, MSc; Kari Klungsøyr, MD, PhD; Anna-Maria Lahesmaa-Korpinen, PhD; Helen Mogun, MS; Mette Nørgaard, MD, PhD; Johan Reutfors, MD, PhD; Henrik Toft Sørensen, MD, DMSc, PhD; Helga Zoega, MA, PhD; Helle Kieler, MD, PhD

J Clin Psychiatry 2023;84(1):22m14430

ABSTRACT

Objective: Most research on safety of attention-deficit/hyperactivity disorder (ADHD) medications during pregnancy concerns central nervous system stimulants, while little is known about the safety of atomoxetine, a primary treatment alternative. We assessed the prevalence of major congenital malformations overall, and cardiac malformations and limb malformations specifically, after first-trimester exposure.

Methods: In this cohort study, we included all approximately 2.4 million pregnancies ending in live births recorded in the population-based nationwide health registers of Denmark, Iceland, Norway, and Sweden (2003–2017) and approximately 1.8 million publicly insured pregnancies ending in live births recorded in the US Medicaid Analytic eXtract (MAX, 2001–2013) health care claims database. We compared the prevalence of major congenital malformations in the newborn among pregnancies exposed and unexposed to atomoxetine. For each country, we calculated prevalence ratios (PRs), crude and stratified by propensity scores (PSs). We pooled the country-specific PS strata to obtain a PR adjusted for potential confounding factors.

Results: We identified 368 pregnancies exposed to atomoxetine during the first trimester in the 4 Nordic countries and 622 in the US. The pooled crude PR for any major congenital malformation was 1.18 (95% CI, 0.88–1.60), and the adjusted PR was 0.99 (95% CI, 0.74–1.34). For cardiac malformations, the adjusted PR was 1.34 (95% CI, 0.86–2.09). For limb malformations, the adjusted PR was 0.90 (95% CI, 0.38–2.16).

Conclusions: After atomoxetine exposure in early pregnancy, we observed no increase in major congenital malformations overall and, although with some uncertainty due to sample size, no statistically increased risk estimates for cardiac malformations and limb malformations.

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Download Free PDF

References (34)

Haervig KB, Mortensen LH, Hansen AV, et al. Use of ADHD medication during pregnancy from 1999 to 2010: a Danish register-based study. Pharmacoepidemiol Drug Saf. 2014;23(5):526–533. PubMed CrossRef
Karlstad Ø, Zoëga H, Furu K, et al. Use of drugs for ADHD among adults-a multinational study among 15.8 million adults in the Nordic countries. Eur J Clin Pharmacol. 2016;72(12):1507–1514. PubMed CrossRef
Louik C, Kerr S, Kelley KE, et al. Increasing use of ADHD medications in pregnancy. Pharmacoepidemiol Drug Saf. 2015;24(2):218–220. PubMed CrossRef
Anderson KN, Ailes EC, Danielson M, et al. Attention-deficit/hyperactivity disorder medication prescription claims among privately insured women aged 15–44 years—United States, 2003–2015. MMWR Morb Mortal Wkly Rep. 2018;67(2):66–70. PubMed CrossRef
Pottegård A, Hallas J, Andersen JT, et al. First-trimester exposure to methylphenidate: a population-based cohort study. J Clin Psychiatry. 2014;75(1):e88–e93. PubMed CrossRef
Diav-Citrin O, Shechtman S, Arnon J, et al. Methylphenidate in pregnancy: a multicenter, prospective, comparative, observational study. J Clin Psychiatry. 2016;77(9):1176–1181. PubMed CrossRef
Nörby U, Winbladh B, Källén K. Perinatal outcomes after treatment with ADHD medication during pregnancy. Pediatrics. 2017;140(6):e20170747. PubMed CrossRef
Huybrechts KF, Broms G, Christensen LB, et al. Association between methylphenidate and amphetamine use in pregnancy and risk of congenital malformations: a cohort study from the international pregnancy safety study consortium. JAMA Psychiatry. 2018;75(2):167–175. PubMed
Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs. 2009;11(3):203–226. PubMed CrossRef
Ornoy A. Pharmacological treatment of attention deficit hyperactivity disorder during pregnancy and lactation. Pharm Res. 2018;35(3):46. PubMed CrossRef
Ornoy A, Koren G. The effects of drugs used for the treatment of attention deficit hyperactivity disorder (ADHD) on pregnancy outcome and breast feeding: a critical review. Curr Neuropharmacol. 2021;19(11):1794–1804. PubMed
Bro SP, Kjaersgaard MI, Parner ET, et al. Adverse pregnancy outcomes after exposure to methylphenidate or atomoxetine during pregnancy. Clin Epidemiol. 2015;7:139–147. PubMed CrossRef
Kolding L, Ehrenstein V, Pedersen L, et al. Associations between ADHD medication use in pregnancy and severe malformations based on prenatal and postnatal diagnoses: a Danish registry-based study. J Clin Psychiatry. 2021;82(1):20m13458. PubMed CrossRef
Drug Approval Package. Strattera (Atomoxetine Hydrochloride) Capsules. Section 8: Use in specific populations. 8.1 Pregnancy. https://pi.lilly.com/us/strattera-pi.pdf. 2002:13–14. Accessed March 22, 2018.
Larsen ER, Damkier P, Pedersen LH, et al; Danish Psychiatric Society; Danish Society of Obstetrics and Gynecology; Danish Paediatric Society; Danish Society of Clinical Pharmacology. Use of psychotropic drugs during pregnancy and breast-feeding. Acta Psychiatr Scand suppl. 2015;132(S445):1–28. PubMed CrossRef
Besag FM. ADHD treatment and pregnancy. Drug Saf. 2014;37(6):397–408. PubMed CrossRef
Freeman MP. ADHD and pregnancy. Am J Psychiatry. 2014;171(7):723–728. PubMed CrossRef
Eddy LD, Jones HA, Snipes D, et al. Associations between ADHD symptoms and occupational, interpersonal, and daily life impairments among pregnant women. J Atten Disord. 2017;23(9):1087054716685839. PubMed
Kittel-Schneider S, Quednow BB, Leutritz AL, et al. Parental ADHD in pregnancy and the postpartum period: a systematic review. Neurosci Biobehav Rev. 2021;124:63–77. PubMed CrossRef
Ludvigsson JF, Håberg SE, Knudsen GP, et al. Ethical aspects of registry-based research in the Nordic countries. Clin Epidemiol. 2015;7:491–508. PubMed CrossRef
Laugesen K, Ludvigsson JF, Schmidt M, et al. Nordic health registry-based research: a review of health care systems and key registries. Clin Epidemiol. 2021;13:533–554. PubMed CrossRef
Löfling L, Bröms G, Bahmanyar S, et al. Maternal and infant characteristics: differences and similarities between the Nordic countries and the US. Clin Epidemiol. 2016;8:285–294. PubMed CrossRef
Maret-Ouda J, Tao W, Wahlin K, et al. Nordic registry-based cohort studies: possibilities and pitfalls when combining Nordic registry data. Scand J Public Health. 2017;45(suppl):14–19. PubMed CrossRef
Langhoff-Roos J, Krebs L, Klungsøyr K, et al. The Nordic medical birth registers: a potential goldmine for clinical research. Acta Obstet Gynecol Scand. 2014;93(2):132–137. PubMed CrossRef
Clapp MA, James KE, Kaimal AJ, et al. Association of Medicaid expansion with coverage and access to care for pregnant women. Obstet Gynecol. 2019;134(5):1066–1074. PubMed CrossRef
Bateman BT, Heide-Jørgensen U, Einarsdóttir K, et al. β-Blocker use in pregnancy and the risk for congenital malformations: an international cohort study. Ann Intern Med. 2018;169(10):665–673. PubMed CrossRef
Furu K, Wettermark B, Andersen M, et al. The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol. 2010;106(2):86–94. PubMed CrossRef
WHO Collaborating Centre for Drug Statistics Methodology. ATC classification Index with DDDs, 2017. Oslo, Norway, 2016.
(CMS) CfMaMS. Medicaid Analytic eXtract (MAX) General Information. CMS.gov website. https://www.cms.gov/Research-Statistics-Data-and-Systems/Computer-Data-and-Systems/MedicaidDataSourcesGenInfo/MAXGeneralInformation. Accessed August 26, 2021.
Carney EW, Kimmel CA. Interpretation of skeletal variations for human risk assessment: delayed ossification and wavy ribs. Birth Defects Res B Dev Reprod Toxicol. 2007;80(6):473–496. PubMed CrossRef
Pottegård A, Christensen Rd, Houji A, et al. Primary non-adherence in general practice: a Danish register study. Eur J Clin Pharmacol. 2014;70(6):757–763. PubMed CrossRef
Vargesson N. Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Res C Embryo Today. 2015;105(2):140–156. PubMed CrossRef
Svensson E, Ehrenstein V, Nørgaard M, et al. Estimating the proportion of all observed birth defects occurring in pregnancies terminated by a second-trimester abortion. Epidemiology. 2014;25(6):866–871. PubMed CrossRef
Kieler H, Malm H, Artama M, et al. Use of antidepressants and association with elective termination of pregnancy: population based case-control study. BJOG. 2015;122(12):1618–1624. PubMed CrossRef